Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MorphoSys AG

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
From MorphoSys AG
Via Business Wire
Tickers MOR
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
From MorphoSys AG
Via Business Wire
Tickers MOR
MorphoSys AG Reports First Quarter 2024 Financial Results
From MorphoSys AG
Via Business Wire
Tickers MOR
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
From MorphoSys AG
Via Business Wire
Tickers MOR
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From MorphoSys AG
Via Business Wire
Tickers MOR
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
From MorphoSys AG
Via Business Wire
Tickers MOR
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
From MorphoSys AG
Via Business Wire
Tickers MOR
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
From MorphoSys AG
Via Business Wire
Tickers MOR
MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
From MorphoSys AG
Via Business Wire
Tickers MOR
MorphoSys AG Reports First Quarter 2023 Financial Results
From MorphoSys AG
Via Business Wire
Tickers MOR
MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From MorphoSys AG
Via Business Wire
Tickers MOR
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
From MorphoSys AG
Via Business Wire
Tickers MOR
MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters
From MorphoSys AG
Via Business Wire
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
From MorphoSys AG
Via Business Wire
Tickers MOR
MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
From MorphoSys AG
Via AccessWire
Tickers MOR MPSYF
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
From MorphoSys AG
Via AccessWire
Tickers MOR MPSYF
MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
From MorphoSys AG
Via AccessWire
Tickers MOR MPSYF
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
From MorphoSys AG
Via Business Wire
Tickers MOR
MorphoSys AG Reports Outcome of Annual General Meeting 2022
From MorphoSys AG
Via AccessWire
Tickers MOR
MorphoSys AG Reports First Quarter 2022 Financial Results
From MorphoSys AG
Via Business Wire
Tickers MOR
Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
From MorphoSys AG
Via AccessWire
Tickers MOR
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
From MorphoSys AG
Via AccessWire
Tickers MOR
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
From MorphoSys AG
Via Business Wire
Tickers MOR
National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
From MorphoSys AG
Via AccessWire
Tickers MOR
Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
From MorphoSys AG
Via AccessWire
Tickers MOR
MorphoSys AG Reports Non-Cash Impairment Charge of € 231 Million on Goodwill After Consolidation of Research and Discovery Functions; Corresponding Increase of Group Operating Expenses in 2021
From MorphoSys AG
Via AccessWire
Tickers MOR
MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report
From MorphoSys AG
Via AccessWire
Tickers MOR
MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
From MorphoSys AG
Via AccessWire
Tickers MOR
MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
From MorphoSys AG
Via AccessWire
Tickers MOR
MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis
From MorphoSys AG
Via AccessWire
Tickers MOR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.